Halloran is pleased to announce that we will be participating in three industry events in the month of September. Thought leaders from Halloran will be speaking on panels, presenting on key trends and meeting with peers to discuss opportunities and challenges facing pharma, biotech, and life sciences.
We are thrilled to announce that Halloran has been recognized on the Inc. 5000 list for the fourth year running. Each year, Inc. magazine names the fastest growing private companies on a prestigious list that exemplifies a high level of success and transformation.
The Food and Drug Administration (FDA) granted orphan drug designation to CT-179, Curtana Pharmaceuticals’ lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high-grade glioma in children.